Ran Nussbaum is a Managing Partner and Co-Founder of The Pontifax Group. Prior to founding Pontifax in 2004, he was Chief Executive Officer of Biomedix and Spearhead Ltd, and a Partner at Israel’s largest business intelligence and strategic consulting firm. He is currently Chairman of the Board of Keros Therapeutics, and a Board member of many of Pontifax’s portfolio companies, including Eloxx Pharmaceuticals, UroGen Pharma, ArQule and Ocon Medical.

Previously, Ran served on the Boards of Kite Pharma (sold to Gilead) and cCAM Biotherapeutics (sold to Merck) and was Chairman of the Boards of Ocon Medical, Nasvax, Spearhead Ltd. and Biomedix.